Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2026)
Neuphoria Therapeutics (NEUP) reported Total Non-Current Liabilities of $4.4 million for Q1 2026, up 54.19% year-over-year from $2.8 million in Q1 2025, and up 4.22% quarter-over-quarter from $4.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has 6 years of Total Non-Current Liabilities data on file, last reported at $4.4 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $4.4 million, up 54.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (up 54.19% YoY), and the FY2025 annual result was $8.4 million, up 53.02% from the prior year.
- Total Non-Current Liabilities grew to $4.4 million in Q1 2026 per NEUP's latest filing, from $4.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $8.4 million in Q2 2025 and troughed at $2.8 million in Q1 2025.
- A 5-year average of $5.0 million and a median of $4.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities slipped 5.26% in 2025, then soared 54.19% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $3.6 million in 2022, then rose by 5.99% to $3.8 million in 2023, then grew by 15.4% to $4.4 million in 2024, then declined by 5.26% to $4.2 million in 2025, then rose by 4.22% to $4.4 million in 2026.
- Business Quant data shows NEUP's Total Non-Current Liabilities at $4.4 million in Q1 2026, $4.2 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 64.76 Mn |
| 10 | Neuphoria Therapeutics | 23.86 Mn | 4.46 Mn | - | 4.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Jun 30, 2024 | 5.50 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Jun 30, 2022 | 3.61 Mn |
| Jun 30, 2021 | 3.32 Mn |